Update on targeted therapies for clear cell renal cell carcinoma

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma

(2010) D. C. Cho et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma

(2010) John D. Hainsworth et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

(2010) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

(2010) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted therapies for renal cell carcinoma: understanding their impact on survival

(2010) Sumanta Kumar Pal et al.   Targeted Oncology

Targeted therapies for non-clear renal cell carcinoma

(2010) Eric A. Singer et al.   Targeted Oncology

Downsizing a Tumor Thrombus of Advanced Renal Cell Carcinoma with Neoadjuvant Systemic Therapy and Resulting Histopathological Effects

(2010) N. Kroeger et al.   UROLOGIA INTERNATIONALIS

Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney

(2009) R. Beroukhim et al.   CANCER RESEARCH

Renal cell carcinoma

(2009) Jorge A Garcia et al.   CURRENT OPINION IN ONCOLOGY

Metastatic Renal Cell Carcinoma: Recent Advances in the Targeted Therapy Era

(2009) Giuseppe Di Lorenzo et al.   EUROPEAN UROLOGY

Long-Term Response in Primary Renal Cancer to Sequential Antiangiogenic Therapy

(2009) Nicholas J. Vogelzang et al.   JOURNAL OF CLINICAL ONCOLOGY

Metastatic Renal Cell Carcinoma: Many Treatment Options, One Patient

(2009) Brian I. Rini   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma

(2009) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma

(2009) Eric Jonasch et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

(2009) Daniel Y.C. Heng et al.   JOURNAL OF CLINICAL ONCOLOGY

Surgical Resection of Renal Cell Carcinoma After Targeted Therapy

(2009) Anil A. Thomas et al.   JOURNAL OF UROLOGY

Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm

(2008) Brian Shuch et al.   BJU INTERNATIONAL

IL-21 induces in vivo immune activation of NK cells and CD8+ T cells in patients with metastatic melanoma and renal cell carcinoma

(2008) Klaus Stensgaard Frederiksen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Targeting tumor angiogenesis with histone deacetylase inhibitors

(2008) Leigh Ellis et al.   CANCER LETTERS

Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2

(2008) Alfredo Toschi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell Carcinoma

(2008) John A. Thompson et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Trial of Adjuvant Thalidomide Versus Observation in Patients With Completely Resected High-Risk Renal Cell Carcinoma

(2008) Vitaly Margulis et al.   UROLOGY